A$11,000 cash and A$7.4 million unused financing capacity at Argent

• A$11,000 cash at 30 September after A$734,000 operating outflows
• A$600,000 drawn under convertible securities facility during quarter
• A$7.4 million of unused financing capacity at quarter end
• Exclusive worldwide-ex-China rights to Tollovir, Tollovid and NutraVir
• CannEpil veterinary programme opened an FDA-CVM INAD file, not approval

Cash falls to A$11,000 as funding remains central

Argent BioPharma Ltd (ASX:RGT) finished the September quarter with A$11,000 in cash, down from A$141,000 three months earlier. Operating activities consumed A$734,000, including A$507,000 in administration and corporate costs, A$149,000 in staff costs and A$48,000 in research and development.

The cash position was supported by A$600,000 received under the company’s A$11 million convertible securities facility. At quarter end, A$3.6 million of that facility had been drawn, leaving A$7.4 million available. Argent also entered into unsecured loan facilities totalling US$500,000 with the same counterparties on 1 October, although the filing does not state how much, if any, had been drawn after quarter end.

On the Appendix 4C calculation, cash plus unused financing represented A$7.411 million of available funding, equivalent to an estimated 10.1 quarters at the reported operating cash-outflow rate. That figure depends heavily on continued access to the financing facility; it is not a measure of cash held in the bank.

NLC antiviral rights add a commercial pillar

Argent is sharpening its strategy around immune modulation and inflammatory disease, with RGT-CA91980 as its lead internally developed programme and CimetrA® as a commercial focus. Alongside those assets, the company has secured exclusive, royalty-bearing rights outside China to commercialise NLC’s Tollovir, Tollovid and NutraVir products, excluding the NLCV-001 clinical-trial formulation.

The agreement covers related formulations, data, trade secrets and know-how, while NLC retains the underlying intellectual property. Argent’s rights are commercial rather than pharmaceutical-development rights, meaning any move into drug development would require separate rights and regulatory approvals. The company said the licensed products will be commercialised alongside CimetrA®, with costs shared across both programmes, following the NLC antiviral licence reported in September.

Royalties are payable separately on each product at 12% of the first US$2.5 million of cumulative net sales, 9% of the next US$2.5 million and 6% thereafter. The arrangement therefore gives Argent access to a broader product portfolio, but its financial contribution will depend on turning those commercial rights into sales.

CannEpil licence removes debt while veterinary pathway advances

Argent has also finalised the global CannEpil® licensing framework with Endovia Health Sciences, formerly Splash Beverage Group. The US$5.5 million upfront consideration was satisfied by forgiving Mercer Street Global Opportunity Fund convertible notes, removing the company’s principal secured liability. Argent retains the intellectual property, manufactures CannEpil® on a cost-plus basis with a margin of up to 20%, and receives a 15% royalty on net revenues.

The licence now covers veterinary applications as well as human therapeutic use. The human royalty remains 15%, while veterinary sales carry a new perpetual 10% royalty. Endovia has begun a US programme targeting cancer-related pain in companion animals, initially canine oncology, with Lupvindol Biosciences leading pharmaceutical development and FDA regulatory strategy. The programme’s CannEpil debt-forgiveness deal previously removed US$5.5 million of secured debt.

FDA-CVM established Investigational New Animal Drug File No. 14145 on 26 August. That is the first formal regulatory milestone for the veterinary programme, but the filing explicitly says it is not FDA approval, conditional approval, confirmation of safety or efficacy, or authorisation to market CannEpil® in the United States.

Bottom Line?

Argent has replaced secured debt with licensing rights and royalties, but the near-term story still rests on financing access and evidence that the expanded portfolio can generate revenue.

Questions in the middle?

• How much of the new US$500,000 unsecured loan facility has been drawn, and on what terms?
• Can the NLC products and CimetrA® produce meaningful commercial receipts before the financing capacity is materially reduced?
• What clinical, regulatory and commercial milestones will follow the CannEpil veterinary INAD file?